Zenas BioPharma Inc logo

Zenas BioPharma Inc

ZBIO
Healthcare|Biotechnology|USA
$28.73
-0.69 (-2.34%)
Tangible Book
$5.38

Upcoming Data Readouts (2)

Jun 2030
Est. completion
P3Multiple Sclerosis (MS) Primary Progressive
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463n=705
Jun 2030
Est. completion
P3Secondary Progressive Multiple Sclerosis
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019n=990

Awaiting Results (3)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2026
P3
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
NCT05786573
Nov 2025
P3
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241
Aug 2025
P2
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311

Recent Press Releases